General Practice
The principal drawback of the crossover trial is that the effects of one treatment may "carry over" and alter the response to subsequent treatments. The usual approach to preventing this is to introduce a washout (no treatment) period between consecutive treatments which is long enough to allow the effects of a treatment to wear off. A variation is to restrict outcome measurement to the latter part of each treatment period. Investigators then need to understand the likely duration of action of a given treatment and its potential for interaction with other treatments.
For example, Chisholm et al used a crossover design to examine the effects of replacing butter with margarine on the lipoprotein profile of subjects with hypercholesterolaemia. 1 Patients were randomised to a six week butter diet followed by a six week margarine diet, or the reverse sequence. Treatment periods were separated by five weeks' washout in which patients returned to their usual diet. The impact on lipoprotein profiles was measured from blood specimens taken in the last week of each experimental period. The assumptions are that six weeks is long enough for an experimental diet to affect lipoprotein profile and that five weeks is long enough for the effects to dissipate.
In the analysis of crossover trials it is conventional to pretest the data for evidence of carry over. If carry over is present the outcome on a given treatment will vary according to its position in the sequence of treatments. This approach is based on the questionable assumption that no carry over is present when a statistical test fails to find one. For example, Chisholm et al's hypercholesterolaemia study concluded that there was no carry over when an analysis of variance found no statistically significant interaction between treatment sequence and outcome. 1 However such tests have limited power and cannot rule out a type II error (wrongly concluding there is no carry over effect).
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If carry over is detected convention suggests this may be dealt with in the analysis in one of two ways. The usual approach is to treat the study as though it were a parallel group trial and confine analysis to the first period alone. The advantages of the crossover are lost, with the wasted expense of discarding the data from the second period. More importantly, the significance test comparing the first periods may be invalid. 3 A second approach, applicable only to studies with at least three treatment periods (ABB/BAA), is Search Search all BMJ Products Search Search bmj.com the first periods may be invalid. 3 A second approach, applicable only to studies with at least three treatment periods (ABB/BAA), is to model the carry over effect and use it to adjust the treatment estimate. Such approaches, while statistically elegant, are based on assumptions which can rarely be justified in practice. 2 The best advice is therefore to avoid using a crossover design if there is any good reason to suppose that carry over effects are likely to occur. A readable approach to the problems of designing and analysing crossover trials is provided by Senn.
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